Top

Clinical and Translational Oncology

Published in:

01-08-2012 | Research Article

Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases. A retrospective analysis of a single center

Authors: Xiujun Chen, Jianping Xiao, Xiangpan Li, Xuesong Jiang, Ye Zhang, Yingjie Xu, Jianrong Dai

Published in: Clinical and Translational Oncology | Issue 8/2012

Abstract

Purpose

To summarize the outcomes of stereotactic radiotherapy (SRT), with or without whole-brain radiotherapy (WBRT), in the treatment of multiple brain metastasis and to explore the status of WBRT and SRT in the management of multiple brain metastasis.

Methods

From May 1995 to April 2010, 98 patients with newly diagnosed, multiple brain metastasis were treated in our center. Forty-four patients were treated with SRT alone for the initial treatment, and 54 were treated with SRT + WBRT. Kaplan–Meier and Cox proportional hazards regression analyses were used for the survival analysis.

Results

The median survival time (MST) was 13.5 months. No difference was observed in MST between the SRT and the SRT + WBRT groups (p = 0.578). The Karnofsky Performance Score at the time of treatment (p = 0.025), the interval time between diagnosis of primary tumor and brain metastasis (P = 0.012) and the situation of extracranial disease (p = 0.018) were significant predictors of survival. The crude distant intracranial recurrence (DIR) rates were 47.7 % in the SRT group and 24.1 % in the SRT + WBRT group (p = 0.018). In addition, 52.3 % patients in the SRT group were free from DIR and did not require WBRT in their whole lives.

Conclusions

Our data suggest that use of SRT as the initial treatment while reserving WBRT as the salvage therapy in case of distant intracranial recurrence made about 50 % of the patients avoid WBRT throughout the course of their lives and may be another optional treatment modality for multiple brain metastases.

Posner JB (1992) Management of brain metastases. Rev Neurol (Paris) 148:477–487

Nussbaum ES, Djalilian HR, Cho KH et al (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781–1788PubMedCrossRef

Delattre JY, Krol G, Thaler HT et al (1988) Distribution of brain metastases. Arch Neurol 45:741–744PubMedCrossRef

Komarnicky LT, Phillips TL, Martz K et al (1991) A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 79–16). Int J Radiat Oncol Biol Phys 20:53–58PubMedCrossRef

Sause WT, Scott C, Kirsch R et al (1993) Phase I/II trial of accelerated fractionation in brainmetastases, RTOG 85-28. Int J Radiat Oncol Biol Phys 26:653–657PubMedCrossRef

Phillips TL, Scott CB, Leibel S et al (1995) Results of a randomized comparison of radiotherapy and bromodeoxyuridine to radiotherapy alone for brain metastases: report of RTOG trial89-05. Int J Radiat Oncol Biol Phys 33:339–348PubMedCrossRef

Murray KJ, Scott C, Greenberg HM et al (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastasis: a report of RTOG9104. Int J Radiat Oncol Biol Phys 39:571–574PubMedCrossRef

Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedCrossRef

Frazier JL, Batra S, Kapor S et al (2010) Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys 76(5):1486–1492PubMedCrossRef

10.

Bhatnagar AK, Flickinger JC, Kondziolka D et al (2006) Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64(3):898–903PubMedCrossRef

11.

Kim SH, Weil RJ, Chao ST et al (2008) Stereotactic radiosurgical treatment of brain metastases in older patients. Cancer 113:834–840PubMedCrossRef

12.

Flannery TW, Suntharalingam M, Regine WF et al (2008) Long-term survival in patients with synchronous, solitary brain metastasis from non–small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 72:19–23PubMedCrossRef

13.

Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH et al (2001) Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51(2):426–434PubMedCrossRef

14.

Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803PubMedCrossRef

15.

Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B, Van Houtte P, Brotchi J, Levivier M (2004) Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 60:218–224PubMedCrossRef

16.

Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491PubMedCrossRef

17.

Rades D, Dziggel L, Haatanen T et al (2011) Scoring system to estimate intracranial control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys 80(4):1122–1127PubMedCrossRef

18.

Kim EY, Maciunas RJ, Williams JM et al (2006) 153 tumor volume is a predictor of overall survival for patients with brain metastases who undergo gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 66(3 Suppl):S86CrossRef

19.

Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD (2006) Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64:898–903PubMedCrossRef

20.

Jawahar A, Shaya M, Campbell P et al (2005) Role of stereotactic radiosurgery as a primary treatment option in the management ofnewly diagnosed multiple (3–6) intracranial metastases. Surg Neurol 64:207–212PubMedCrossRef

21.

Sheehan J, Kondziolka D, Flickinger J, Lunsford LD (2005) Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 102(Suppl.):247–254

22.

Selek U, Chang EL, Hassenbusch SJ III et al (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59:1097–1106PubMedCrossRef

23.

Shaw Edward, Scott Charles, Souhami Luis et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain Metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298PubMedCrossRef

24.

Kim YJ, Cho KH, Kim JY et al (2010) Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.05.033

25.

Shehata MK, Young B, Reid B et al (2004) Stereotactic radiosurgery of 468 brain metastases < or =2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 59:87–93PubMedCrossRef

26.

Chidel MA, Suh JH, Reddy CA et al (2000) Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 47:993–999PubMedCrossRef

27.

Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044PubMedCrossRef

28.

Aoyama H, Tago M, Katoh N et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395PubMedCrossRef

29.

Martin K, Riccardo S, Ufuk A et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141CrossRef

30.

Alexander S, Kyounghwa B, Elizabeth MG et al (2010) Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. doi:10.1200/JCO.2010.29.1609

Title: Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases. A retrospective analysis of a single center
Authors: Xiujun Chen
Jianping Xiao
Xiangpan Li
Xuesong Jiang
Ye Zhang
Yingjie Xu
Jianrong Dai
Publication date: 01-08-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 8/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0849-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2012

Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients

Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

Online First service, a further step forward

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome

Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer